GlobalRPh Renal Dosing Masterv6.6
Source review / handoff

Linezolid

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Check source scope before reading a dose

GlobalRPh RX List - Zyvox

Product / population
Linezolid; parent-drug renal guidance and dialysis timing.
Renal method
Renal impairment categories; no numeric cutoff for label adjustment.
Source revision
Revised July 2023
Retrieved
2026-09-07
Local review status
Locally imported selected source sections; independent clinical review pending. Not a complete prescribing monograph.

Documented differences and cautions on this drug

All record notes are retained here, including notes about sources not selected in this review.

Label guidance versus selected expert dose reduction

The label does not require routine renal reduction. UCSF describes a selected strategy for stable patients with CrCl below 30 and an anticipated course longer than 10 days, after the initial 72 hours.

What to reconcile: Do not apply a reduced regimen universally. Retain the clinical-stability, duration, monitoring and specialist qualifiers.

Source difference identified; final patient-specific adjudication required.

Open this note and its source references

Linezolid: qualified expert reduction versus label no-adjustment

UCSF describes an optional expert reduction for selected stable patients receiving a prolonged course, rather than a universal renal reduction. Its dialysis table remains separately stated.

What to reconcile: Document the source and qualifying clinical context; involve infectious diseases and consider drug-level monitoring. Do not apply the expert exception indiscriminately.

Source-specific interpretation; independent clinician adjudication pending.

Open this note and its source references
Rxlist

GlobalRPh RX List - Zyvox

Open original reference

GlobalRPh-hosted RX List · Linezolid; parent-drug renal guidance and dialysis timing.

Renal method: Renal impairment categories; no numeric cutoff for label adjustment.
Source date: Revised July 2023
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
No adjustment within stated limits. This does not establish dosing outside the studied renal range or population.

Locally imported selected source sections; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

No renal dose adjustment is recommended because parent-drug concentrations are similar across impairment groups. The two primary metabolites accumulate as renal function declines; weigh the potential risks of that accumulation. Administer after hemodialysis. Information about peritoneal dialysis is unavailable. This label statement differs from selected expert strategies for prolonged treatment with monitoring; it does not establish that those strategies apply to every patient.

RDM33-rxlist-linezolid-C1 · Source locator: Clinical pharmacology: renal impairment and hemodialysis.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/zyvox-drug/
Retrieved
2026-09-07
Renal-function method
Renal impairment categories; no numeric cutoff for label adjustment.
Source date/version
Revised July 2023
Hash meaning
SHA-256 of the local authored summary only; original HTML/PDF/SPL bytes are not bundled or hashed.
Local summary SHA-256
687ca905e4318ddf5b05a5ed74b75c62007b75a8a4ea47eb15377f31f75272e4

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=linezolid&s1=RDM33-rxlist-linezolid&h1=a68b8cf868a68bb6279dab629b84a900242007b002f8b7663d9e8f6d40fdcf86